Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Product/Service, Trade Show

New Phase 2a Clinical Trial Results Demonstrate Endeavor BioMedicines' ENV-101 Improved Lung Function and Reversed Key Measures of Lung Fibrosis in Patients With Idiopathic Pulmonary Fibrosis


Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial that demonstrate the company's lead investigational candidate, ENV-101, improved lung function and reversed key measures of lung fibrosis in patients with idiopathic pulmonary fibrosis (IPF) over a 12-week period. The results, which also showed that ENV-101 had an acceptable tolerability profile, were presented for the first time today in a late-breaking oral session at the American Thoracic Society 2024 (ATS 2024) International Conference.

"There is a tremendous need for IPF treatments that do more than slow the inevitable decline of lung function," said Toby M. Maher, M.D., Ph.D., Professor of Medicine and Director of Interstitial Lung Disease at Keck School of Medicine, University of Southern California, Los Angeles, who presented the data. "These preliminary signs of clinical and antifibrotic activity suggest that ENV-101 has the potential to change the trajectory of this otherwise relentless disease."

Current standard-of-care therapies do not address the underlying cause of IPF. They slow the decline of lung function, but do not stop or reverse it, and they have tolerability issues that limit their long-term use in most patients. ENV-101 is designed to block a cellular wound-healing pathway known as Hedgehog (Hh) that is abnormally activated in fibrotic lung diseases, such as IPF, and causes the continuous pathophysiologic buildup of scar tissue in the lungs.

Key findings from the ENV-101 Phase 2a clinical trial in IPF presented today at the ATS 2024 International Conference include:

"These trial results suggest ENV-101 could have transformational clinical benefits for individuals with IPF, who are in need of therapies that change treatment expectations - from slowing disease progression to potentially reversing it," said Paul A. Frohna, M.D., Ph.D., Chief Medical Officer, Endeavor BioMedicines. "We look forward to further evaluating ENV-101's potential in the upcoming WHISTLE-PF clinical trial."

Based on the ENV-101 Phase 2a trial results shared today, Endeavor BioMedicines intends to initiate the Phase 2 WHISTLE-PF (Wound-remodeling Hedgehog-inhibitor ILD Study Testing Lung Function Endpoints -PF) trial. This trial is expected to include a global Phase 2b cohort in individuals with IPF and a parallel Phase 2 cohort in individuals with progressive pulmonary fibrosis (PPF). Endeavor BioMedicines recently announced the closing of a $132.5 million Series C financing that will support clinical development of ENV-101 in IPF and PPF.

About the ENV-101 Phase 2a Trial
The randomized, double-blind, placebo-controlled Phase 2a clinical trial (NCT04968574) evaluated the safety and efficacy of ENV-101 vs. placebo in 41 patients with confirmed idiopathic pulmonary fibrosis. Patients at 16 sites in five countries were randomized 1:1 to receive 200 mg of ENV-101 or placebo once daily for 12 weeks. The primary endpoint for the trial was overall safety of ENV-101. Secondary endpoints included change from baseline to week 12 on lung function, measured by forced vital capacity (FVC) mL and percent predicted FVC (ppFVC), and patient reported outcomes based on the UCSD shortness-of-breath questionnaire. Key exploratory endpoints included mean change from baseline in total lung capacity (TLC) and change from baseline for % quantitative interstitial lung disease (QILD), % quantitative lung function (QLF) and % quantitative ground glass (QGG), as measured by high-resolution computed tomography (HRCT).

About Idiopathic Pulmonary Fibrosis
IPF is a chronic, progressive lung disease that affects more than 100,000 adults in the United States. Although the exact cause of IPF is unknown, various environmental factors can deliver repeated injuries to lung cells that trigger abnormal wound-healing processes and life-threatening lung scarring. IPF is a chronic disease with limited treatment options and a very poor prognosis: the average life expectancy is only three to five years after diagnosis.

About ENV-101
Endeavor BioMedicines' investigational medicine, ENV-101, is a Hedgehog signaling pathway inhibitor. By binding to and inhibiting a key receptor in the Hedgehog pathway, ENV-101 is designed to stop the abnormal accumulation of myofibroblasts that cause fibrosis. This may resolve the excessive wound-healing process seen in IPF and PPF, creating the potential to reverse fibrosis and improve lung volume and function.

About Endeavor BioMedicines
Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases. Endeavor's lead candidate, ENV-101, is an inhibitor of the Hedgehog signaling pathway in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The company's second candidate, ENV-501, is a HER3 antibody-drug conjugate (ADC) for the treatment of HER3-positive solid tumors. More information is available at www.endeavorbiomedicines.com and on LinkedIn or X.


These press releases may also interest you

at 22:00
Innovative technology brand TECNO today unveiled SPARK 20 Pro 5G, the first 5G device in the SPARK 20 Series. As a powerful new 5G smartphone, the latest addition to the Series offers compelling performance boosted by an outstanding high-speed 5G...

at 21:32
METZ Display, a sub-brand of SKYWORTH and a provider of innovative interactive displays for education and business. The announcement of Artificial Intelligence Technologies LLC Dubai as the authorized exclusive distributor for the UAE market as well...

at 21:00
Casio Computer Co., Ltd. announced today the release of the GBD-300, a new addition to the sports-driven G-SQUAD line in the G-SHOCK family of shock-resistant watches. These new watches feature a slim, compact profile that offers an even more...

at 21:00
TIER IV, a pioneer in open-source software and autonomous driving technology, and Suzuki, one of Japan's leading car and motorcycle manufacturers, have entered into a capital and business alliance aimed at accelerating the development and...

at 21:00
TIER IV, a pioneer in open-source software for autonomous driving systems, proudly announces the successful extension of its Series B funding round, securing an additional US$54 million (¥8.5 billion). This brings the total Series B funding to US$132...

at 20:07
The A' Design Award & Competition, a very prominent and highly influential international design accolade, is thrilled to announce its call for entries for the 2025 edition. Since its inception in 2008, the A' Design Award has been recognizing,...



News published on and distributed by: